> Roche ($RHHBY) and Bayer have expanded their companion diagnostics collaboration into multiple projects. Story
> Harvard Medical School and Columbia University won grants of about $12.3 million this year from the National Institute of Allergy and Infectious Diseases to develop translational research centers focused on molecular diagnostics technologies. Story (reg. req)
> Exosome Diagnostics raised a $27 million Series B round, led by Qiagen ($QGEN) and Arcus Ventures, to help propel its prostate cancer urine test to market. Story
> Seattle's Pacific Biomarkers will use its biomarker assays in a collaboration deal with Shanghai's WuXi PharmaTech ($WX) focused on the development of new treatments. Release
> Quest Diagnostics ($DGX) said it will buy Summit Health, an Arizona company that provides finger-stick diagnostics and other biometric screenings. Financial terms were not disclosed. Release
> NeuroMetrix ($NURO) plans to seek regulatory approval in Japan for its point-of-care test to detect diabetic peripheral neuropathy. Release